ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0279

Therapeutic Exploration of Immune Checkpoint Inhibitor Induced Inflammatory Arthritis In Vivo
Abstract Number: 0280

Immunosuppression in the Treatment of Susac Syndrome: A Retrospective Evaluation of the Largest Cohort of Susac Syndrome
Abstract Number: 0281

Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Abstract Number: 0282

DNA Methylation Markers in Peripheral Blood as Effective Diagnostic Biomarkers for Adult-onset Still’s Disease
Abstract Number: 0283

Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies
Abstract Number: 0284

Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases
Abstract Number: 0285

Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis
Abstract Number: 0286

Relationship Between High Resolution Computed Tomography(HRCT) Quantitative Scores and Physiological and Clinical Features in Antisynthetase Syndrome Related Interstitial Lung Disease
Abstract Number: 0287

6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease
Abstract Number: 0288

Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)
Abstract Number: 0289

Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity
Abstract Number: 0290

Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy
Abstract Number: 0291

Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Abstract Number: 0292

Comparison of Cardiovascular Risk of Myositis Patients and the General Population
Abstract Number: 0293

Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].